Abstract:Safety evaluation is a continual and iterative process throughout the drug development life cycle and requires long time horizons and large amounts of data to fully understand the safety profile of a medical product. Although randomized clinical trials (RCT) provide high-quality data for an initial assessment of safety signals, the safety signals may not all have been known at the time of approval because safety data collected from RCT only involve a relatively small number of subjects during a relatively short follow-up period. The increased accumulation of post-marketing real-world data (RWD) presents an opportunity to utilize them for safety decision-making; these include identifying new safety signals, further characterization of safety concerns that are raised in pre-marketing RCT, and further generalization of RCT findings to the broader patient populations not previously studied in RCT. In this paper, we use cardiovascular safety outcome trial for antidiabetic therapies as an illustrative example and discuss how integrative analysis of RCT and observational study data can answer regulatory concerns about cardiovascular risk in a post-marketing setting. A novel statistical analysis strategy is proposed to combine both sources of safety data in a data fusion approach. The proposed approach includes three stages: (1) feasibility analysis that uses an RCT to validate an observational study, applying estimand framework and emulating RCT with RWD; (2) integrative analysis that combines evidence from the RCT and observational study data cooperatively; and (3) sensitivity analysis that examines the consistency of the previous analyses. Two potential utilities of the proposed integrative analysis for the cardiovascular safety outcome trial are discussed.

A safety estimand for late phase clinical trials where the analysis period varies over the subjects

Estimand Framework and Statistical Considerations for Integrated Analysis of Clinical Trial Safety Data

On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies

Defining estimands using a mix of strategies to handle intercurrent events in clinical trials

A novel estimand to adjust for rescue treatment in clinical trials

Defining estimands in clinical trials: A unified procedure

A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials

Estimands in Hematologic Oncology Trials

Tree‐temporal scan statistics for safety signal detection in vaccine clinical trials

Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

Applying the estimands framework to non-inferiority trials: guidance on choice of hypothetical estimands for non-adherence and comparison of estimation methods

Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial

Treatment Effect Quantification for Time-to-event Endpoints -- Estimands, Analysis Strategies, and beyond

Translating questions to estimands in randomized clinical trials with intercurrent events

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and a roadmap for the future of safety analyses in clinical trials

Estimands in clinical trials of complex disease processes

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance

Integrative Analysis of Randomized Clinical Trial and Observational Study Data to Inform Post-marketing Safety Decision-Making